| Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript |
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Brendan Smith - TD Cowen Gil Blum - Needham & Company George Farmer - Scotiabank Debanjana Chatterjee - Jones Li Chen - H.C. Wainwright Operator Thank you for standing by, and welcome to Absci's First Quarter 2025 Business Update and Financial and Operating Results Conference Call. |
seekingalpha.com |
2025-05-14 02:45:01 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates |
Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2025-05-13 22:30:32 |
Czytaj oryginał (ang.) |
| Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results |
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease |
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-TL1As Interim data anticipated in the second half of 2025 VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineered with Absci's generative AI platform. |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 |
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. |
globenewswire.com |
2025-04-14 20:05:00 |
Czytaj oryginał (ang.) |
| Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market |
Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offers potential upside but increases burn rates and development risks. Strategic partnerships, like those with AMD and AstraZeneca, validate Absci's platform but have yet to generate significant revenue. |
seekingalpha.com |
2025-04-03 19:15:01 |
Czytaj oryginał (ang.) |
| Which Healthcare Stock Is the Best Buy Right Now? |
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time. |
marketbeat.com |
2025-03-31 11:15:09 |
Czytaj oryginał (ang.) |
| Absci to Participate in Upcoming Investor Conferences |
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. |
globenewswire.com |
2025-03-26 10:00:00 |
Czytaj oryginał (ang.) |
| Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. |
benzinga.com |
2025-03-19 10:15:46 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript |
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and CBO Christian Stegmann - SVP of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Vikram Purohit - Morgan Stanley Gil Blum - Needham & Company Debanjana Chatterjee - Jones Operator Thank you for standing by and welcome to Absci's Fourth Quarter and Full Year 2024 Business Update and Financial Operating Results Conference call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-03-18 21:37:41 |
Czytaj oryginał (ang.) |
| Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results |
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 |
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. |
globenewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company granted a non-statutory stock option to purchase an aggregate of 162,800 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-04 18:00:00 |
Czytaj oryginał (ang.) |
| Absci to Participate in the KeyBanc Capital Markets Healthcare Forum |
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. |
globenewswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| Absci to Participate in the TD Cowen 45th Annual Health Care Conference |
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA. |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside |
Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential. |
benzinga.com |
2025-01-22 15:22:46 |
Czytaj oryginał (ang.) |
| Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY. |
globenewswire.com |
2025-01-22 10:00:00 |
Czytaj oryginał (ang.) |
| Absci Looks Cheap And Positioned For Growth With AMD's AI Backing |
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. |
seekingalpha.com |
2025-01-13 04:05:57 |
Czytaj oryginał (ang.) |
| Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery |
Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics |
globenewswire.com |
2025-01-10 09:30:00 |
Czytaj oryginał (ang.) |
| Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery |
$20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software $20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health |
Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications Collaboration leverages Absci's leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript |
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Srikripa Devarakonda – Truist Securities Brendan Smith - TD Cowen George Farmer – Scotiabank Vamil Divan - Guggenheim Securities Operator Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. |
seekingalpha.com |
2024-11-12 12:01:49 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates |
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-11-12 11:51:30 |
Czytaj oryginał (ang.) |
| Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results |
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration |
globenewswire.com |
2024-11-12 09:30:00 |
Czytaj oryginał (ang.) |
| Absci to Host R&D Day on December 12, 2024 |
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City. |
globenewswire.com |
2024-11-07 10:00:00 |
Czytaj oryginał (ang.) |
| Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024 |
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024. |
globenewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile |
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. |
seekingalpha.com |
2024-10-03 16:36:55 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August. |
fool.com |
2024-08-30 14:30:00 |
Czytaj oryginał (ang.) |
| Absci to Participate in Upcoming Investor Conferences |
VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. |
globenewswire.com |
2024-08-21 12:00:00 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript |
Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call. |
seekingalpha.com |
2024-08-17 03:50:29 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates |
Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2024-08-14 22:31:07 |
Czytaj oryginał (ang.) |
| Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results |
Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development |
globenewswire.com |
2024-08-14 20:01:00 |
Czytaj oryginał (ang.) |
| Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI |
The collaboration unites Absci's Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics The collaboration unites Absci's Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics |
globenewswire.com |
2024-08-12 12:00:00 |
Czytaj oryginał (ang.) |
| Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships |
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships |
seekingalpha.com |
2024-07-28 05:24:46 |
Czytaj oryginał (ang.) |
| Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 |
VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024. |
globenewswire.com |
2024-07-10 12:00:00 |
Czytaj oryginał (ang.) |
| Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-07-03 20:00:00 |
Czytaj oryginał (ang.) |
| Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference |
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. |
globenewswire.com |
2024-05-28 12:00:00 |
Czytaj oryginał (ang.) |
| 7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs |
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks? |
investorplace.com |
2024-05-16 11:15:00 |
Czytaj oryginał (ang.) |
| Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript |
Absci Corporation. (NASDAQ:ABSI ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasson – Chief Financial Officer and Chief Business Officer Christian Stegmann – SVP of Drug Creation Conference Call Participants Kripa Devarakonda – Truist Securities George Farmer – Scotia Bank Jacqueline Kisa – TD Cowen Steve Dechert - KeyBanc Capital Markets Li Chen – H.C. |
seekingalpha.com |
2024-05-14 17:30:24 |
Czytaj oryginał (ang.) |
| Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results |
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. |
globenewswire.com |
2024-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| Absci (ABSI) to Report Q1 Earnings: Here's What to Expect |
The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results. |
zacks.com |
2024-05-07 14:16:22 |
Czytaj oryginał (ang.) |